Cover Image
市場調查報告書

疣的開發中產品分析

Warts - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200501
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
疣的開發中產品分析 Warts - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 81 Pages
簡介

疣是指人類乳突病毒(HPV)引發,小而無痛的部分皮膚腫瘤。疣存在許多種類,有出現在手上一般的疣,或是臉部、前額出現平板的疣,性器上產生的尖形濕疣,腳底出現的足部疣,手指甲·腳指甲下和周圍產生的指甲下·指甲周圍疣等。主要的症狀有傷口附近皮膚極黑或極白,前額、臉頰、手腕、腳有許多小而平滑的傷口、手、腳指甲下或周圍產生凹凸狀的腫瘤,腳底的橢圓狀傷口等。形狀皆是平坦而微微鼓起,伴隨有壓迫感,成為小小硬硬的傷口或腫塊。想要持續性除掉疣時有使用Podophyllin和水楊酸等醫藥品處方,但也有使用外科手術和冷凍(冷凍療法)、電燒方來除去。

本報告提供全球各國治療疣用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

疣概要

治療藥的開發

  • 疣開發中產品:概要
  • 疣開發中產品:比較分析

各企業開發中的疣治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

疣治療藥:開發中的產品的一覽(各企業)

疣治療藥的開發企業

  • Helix BioPharma Corp.
  • CEL-SCI Corporation
  • NanoViricides, Inc.
  • 3M Drug Delivery Systems
  • G&E Herbal Biotechnology Co., Ltd.
  • Anaconda Pharma
  • Foamix Ltd.
  • BioMAS Ltd.
  • ViroStatics, srl
  • Cutanea Life Sciences
  • Burke Pharmaceuticals, LLC
  • Agilvax, Inc.
  • Nielsen Biosciences, Inc.

疣病:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 干擾素(interferon)·Alpha-2b (基因重組)
  • AS-101
  • SRT-100
  • AP-611074
  • Candida Albicans Antigen
  • (digoxin + furosemide)
  • 白血球白細胞介素
  • A-101
  • BURKE-201
  • AX-03
  • HerpeCide-I
  • imiquimod
  • 854-A
  • PP-210
  • Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts

疣治療藥:最新的藥物簡介

疣治療藥:暫停的計劃

疣治療藥:開發中止的產品

疣相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿(全8件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8999IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H1 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 15, 1, 6 and 3 respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Warts - Overview
  • Warts - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Warts - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Warts - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Aclaris Therapeutics Inc
    • Agilvax Inc
    • Aviragen Therapeutics Inc
    • Biogenomics Ltd
    • BioMAS Ltd
    • Cutanea Life Sciences Inc
    • Cytovation AS
    • Foamix Pharmaceuticals Ltd
    • G&E Herbal Biotechnology Co Ltd
    • Laboratories Ojer Pharma SL
    • LEO Pharma A/S
    • Nielsen Biosciences Inc
    • Novan Inc
    • Novartis AG
    • Promius Pharma LLC
    • RXi Pharmaceuticals Corp
    • Tamir Biotechnology Inc
    • Verrica Pharmaceuticals Inc
    • Zydus Cadila Healthcare Ltd
  • Warts - Drug Profiles
    • (digoxin + furosemide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Albicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AX-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTA-074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CyPep-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFD-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FIT-039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • furosemide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omiganan pentahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • povidone iodine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Samcyprone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Warts - Dormant Projects
  • Warts - Discontinued Products
  • Warts - Product Development Milestones
    • Featured News & Press Releases
      • Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
      • Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
      • Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
      • Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
      • May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
      • Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
      • Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
      • May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
      • May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
      • Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
      • May 07, 2003: Henderson Morley: Signed Licensing Agreement
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Warts, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Warts - Pipeline by 3M Drug Delivery Systems, H1 2017
  • Warts - Pipeline by Aclaris Therapeutics Inc, H1 2017
  • Warts - Pipeline by Agilvax Inc, H1 2017
  • Warts - Pipeline by Aviragen Therapeutics Inc, H1 2017
  • Warts - Pipeline by Biogenomics Ltd, H1 2017
  • Warts - Pipeline by BioMAS Ltd, H1 2017
  • Warts - Pipeline by Cutanea Life Sciences Inc, H1 2017
  • Warts - Pipeline by Cytovation AS, H1 2017
  • Warts - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
  • Warts - Pipeline by Laboratories Ojer Pharma SL, H1 2017
  • Warts - Pipeline by LEO Pharma A/S, H1 2017
  • Warts - Pipeline by Nielsen Biosciences Inc, H1 2017
  • Warts - Pipeline by Novan Inc, H1 2017
  • Warts - Pipeline by Novartis AG, H1 2017
  • Warts - Pipeline by Promius Pharma LLC, H1 2017
  • Warts - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Warts - Pipeline by Tamir Biotechnology Inc, H1 2017
  • Warts - Pipeline by Verrica Pharmaceuticals Inc, H1 2017
  • Warts - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Warts - Dormant Projects, H1 2017
  • Warts - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Warts, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top